Delving into the Latest Updates on 177Lu-LNC1003 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Radionuclide Drug Conjugates (RDC), Therapeutic radiopharmaceuticals

Synonyms-

Target

PSMA

Action

modulators

Mechanism

PSMA modulators(Prostate-specific membrane antigen modulators)

Therapeutic Areas

NeoplasmsUrogenital Diseases

Active Indication

Metastatic castration-resistant prostate cancerPSMA-Positive Castration-Resistant Prostatic CancerPSMA-Positive Prostatic Cancer

Inactive Indication-

Originator Organization

Yantai Dongcheng Biochemicals Co., Ltd.

Active Organization

Yantai Lannacheng Biotechnology Co., Ltd.

Yantai Dongcheng Biochemicals Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.

login

or

view full example data

Boost your research with our ADC technology data.

This proposal is a phase I, open-label study of a 3-Dose Regimen of Escalating Doses of 177Lu-LNC1003 Injection in patients with PSMA-positive mCRPC.
In the clinical development, we aim to demonstrate the following:
1. Determination of the therapeutic dose(s) to be used in the expansion phase.
2. Demonstration of the safety and tolerability of 177Lu-LNC1003 at therapeutic doses.
The treatment regimen will consist of a single-dose intravenous administration of 177Lu-LNC1003 Injection per 6-week cycle, for a total of 2 cycles. The dose per cycle will be fixed for each patient and will be escalated in 3 different dose levels

Start Date07 May 2025

Sponsor / Collaborator

Yantai Lannacheng Biotechnology Co., Ltd.

CTR20240128

/ Not yet recruitingPhase 1

一项在前列腺特异性膜抗原（PSMA）阳性的转移性去势抵抗性前列腺癌（mCRPC）患者中评价177Lu-LNC1003注射液的安全性、耐受性、药代动力学、辐射剂量学和初步疗效的单中心、剂量递增、I期临床试验

[Translation] A single-center, dose-escalation, phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, radiation dosimetry, and preliminary efficacy of 177Lu-LNC1003 injection in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC)

评价177Lu-LNC1003注射液的安全性、耐受性、剂量限制性毒性（DLT）、最大耐受剂量（MTD）；确定177Lu-LNC1003注射液II期研究推荐剂量（RP2D）；

[Translation]

Evaluate the safety, tolerability, dose-limiting toxicity (DLT), and maximum tolerated dose (MTD) of 177Lu-LNC1003 injection; Determine the recommended dose (RP2D) for the Phase II study of 177Lu-LNC1003 injection;

Start Date-

Sponsor / Collaborator

Yantai Lannacheng Biotechnology Co., Ltd.

100 Clinical Results associated with 177Lu-LNC1003

Login to view more data

100 Translational Medicine associated with 177Lu-LNC1003

Login to view more data

100 Patents (Medical) associated with 177Lu-LNC1003

Login to view more data

100 Deals associated with 177Lu-LNC1003

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic castration-resistant prostate cancer	Phase 1	-	Yantai Lannacheng Biotechnology Co., Ltd.	07 May 2025
PSMA-Positive Castration-Resistant Prostatic Cancer	Phase 1	China	Yantai Lannacheng Biotechnology Co., Ltd.	16 Jan 2024
PSMA-Positive Prostatic Cancer	IND Approval	United States	Yantai Dongcheng Biochemicals Co., Ltd.	05 May 2023